![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Inhibrx Biosciences Inc | NASDAQ:INBX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.30 | 2.23% | 13.73 | 12.85 | 14.45 | 13.79 | 13.26 | 13.53 | 25,072 | 21:00:04 |
SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the Company will be presenting at the Connective Tissue Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place November 10-13, 2021.
CTOS Virtual Presentation Details:
Title: Safety and Efficacy of the Tetravalent Death Receptor 5 Agonist INBRX-109 in Patients with Conventional Chondrosarcoma: Update from the Phase 1 Expansion Cohort
Lead Author: Vivek Subbiah, MD
Abstract: 1082377, (P 018)
Oral Presentation on Thursday, November 11th at 1:29 p.m. – 1:36 p.m. Eastern Time
Title: Tetravalent Death Receptor 5 Agonist INBRX-109 in Ewing Sarcoma: Planned Phase 1 Cohort Expansion Guided by Preclinical Data
Lead Author: Emily Rowell, PhD
Abstract: 1818985, (P 090)
Poster Presentation on Thursday, November 11th at 2:30 p.m. – 3:15 p.m. Eastern Time
Additionally, the Company will be presenting at the following upcoming virtual investor conferences:
The scientific posters and presentation will be accessible through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations. The investor conference presentations will be webcast live and will also be accessible through the same link. The webcasts will be available for at least 60 days following the event.
About Inhibrx, Inc.
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.
Investor and Media Contact:
Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260
View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-scientific-and-investor-conferences-301413398.html
SOURCE Inhibrx, Inc.
Copyright 2021 PR Newswire
1 Year Inhibrx Biosciences Chart |
1 Month Inhibrx Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions